247 related articles for article (PubMed ID: 35621685)
1. De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma-Where Are We Now?
Silver JA; Turkdogan S; Roy CF; Subramaniam T; Henry M; Sadeghi N
Curr Oncol; 2022 May; 29(5):3668-3697. PubMed ID: 35621685
[TBL] [Abstract][Full Text] [Related]
2. De-Escalation Treatment for Human Papillomavirus-Related Oropharyngeal Cancer: Questions for Practical Consideration.
Chen AM
Oncology (Williston Park); 2023 Jul; 37(7):281-287. PubMed ID: 37499250
[TBL] [Abstract][Full Text] [Related]
3. A proposal for risk-based and strategy-adapted de-escalation in human papillomavirus-positive oropharyngeal squamous cell carcinoma.
Wotman MT; Miles BA; Bakst RL; Posner MR
Cancer; 2021 Dec; 127(23):4330-4338. PubMed ID: 34379804
[No Abstract] [Full Text] [Related]
4. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Masterson L; Moualed D; Masood A; Dwivedi RC; Benson R; Sterling JC; Rhodes KM; Sudhoff H; Jani P; Goon P
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD010271. PubMed ID: 24532092
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus-related oropharyngeal carcinoma.
Saito Y; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ota I; Yokota T; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R
Jpn J Clin Oncol; 2022 Jul; 52(7):700-706. PubMed ID: 35383359
[TBL] [Abstract][Full Text] [Related]
6. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.
Masterson L; Moualed D; Liu ZW; Howard JE; Dwivedi RC; Tysome JR; Benson R; Sterling JC; Sudhoff H; Jani P; Goon PK
Eur J Cancer; 2014 Oct; 50(15):2636-48. PubMed ID: 25091798
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.
Rosenberg AJ; Vokes EE
Oncologist; 2021 Jan; 26(1):40-48. PubMed ID: 32864799
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma.
Ang KK; Sturgis EM
Semin Radiat Oncol; 2012 Apr; 22(2):128-42. PubMed ID: 22385920
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus oropharynx carcinoma: Aggressive de-escalation of adjuvant therapy.
Moore EJ; Van Abel KM; Routman DM; Lohse CM; Price KAR; Neben-Wittich M; Chintakuntlawar AV; Price DL; Kasperbauer JL; Garcia JJ; Hinni ML; Patel SH; Janus JR; Foote RL; Ma DJ
Head Neck; 2021 Jan; 43(1):229-237. PubMed ID: 32969095
[TBL] [Abstract][Full Text] [Related]
10. Special Issue about Head and Neck Cancers: HPV Positive Cancers.
Economopoulou P; Kotsantis I; Psyrri A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403287
[TBL] [Abstract][Full Text] [Related]
11. De-escalation treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease.
Stock GT; Bonadio RRCC; de Castro G
Curr Opin Oncol; 2018 May; 30(3):146-151. PubMed ID: 29474271
[TBL] [Abstract][Full Text] [Related]
12. Human Papillomavirus and Squamous Cell Carcinoma of Unknown Primary in the Head and Neck Region: A Comprehensive Review on Clinical Implications.
Larsen MHH; Channir HI; von Buchwald C
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372502
[TBL] [Abstract][Full Text] [Related]
13. De-Escalating Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma.
Economopoulou P; Kotsantis I; Psyrri A
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578368
[TBL] [Abstract][Full Text] [Related]
14. The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
Haring CT; Dermody SM; Yalamanchi P; Kang SY; Old MO; Chad Brenner J; Spector ME; Rocco JW
Oral Oncol; 2022 Mar; 126():105776. PubMed ID: 35183912
[TBL] [Abstract][Full Text] [Related]
15. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
16. A comparison of oncological outcomes between transoral surgical and non-surgical treatment protocols in the management of oropharyngeal squamous cell carcinoma.
Kao SS; Micklem J; Ofo E; Edwards S; Dhatrak D; Foreman A; Krishnan S; Hodge JC
J Laryngol Otol; 2018 Apr; 132(4):349-355. PubMed ID: 28480836
[TBL] [Abstract][Full Text] [Related]
17. Treatment preferences in human papillomavirus-associated oropharyngeal cancer.
Windon MJ; D'Souza G; Fakhry C
Future Oncol; 2018 Oct; 14(24):2521-2530. PubMed ID: 30265132
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy in Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma. Cetuximab is Inferior to Cisplatin - is the Case now Closed?
Donnelly O; Kelly C; Iqbal MS
Clin Oncol (R Coll Radiol); 2022 Dec; 34(12):783-785. PubMed ID: 35945073
[No Abstract] [Full Text] [Related]
19. Human Papillomavirus-Directed Therapeutics for Human Papillomavirus-Associated Oropharyngeal Cancer.
Campbell JS; Pai SI
Cancer J; 2022 Sep-Oct 01; 28(5):407-415. PubMed ID: 36165730
[TBL] [Abstract][Full Text] [Related]
20. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
Ma DJ; Price KA; Moore EJ; Patel SH; Hinni ML; Garcia JJ; Graner DE; Foster NR; Ginos B; Neben-Wittich M; Garces YI; Chintakuntlawar AV; Price DL; Olsen KD; Van Abel KM; Kasperbauer JL; Janus JR; Waddle M; Miller R; Shiraishi S; Foote RL
J Clin Oncol; 2019 Aug; 37(22):1909-1918. PubMed ID: 31163012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
